Global HPV Vaccine Comparison in Girls Aged 9-14 Years
28 Feb 2018
Conducted at 21 sites in Hong Kong, France, Singapore and Sweden, this study on the “Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9–14 years: Results to month 36 from a randomized trial” shows the two-dose AS04-HPV-16/18 to elicit superior antibody responses in participants.
Such result supports the switch from the initially licensed 3-dose schedule to the recent 2-dose schedule for HPV vaccines, which is likely to facilitate the introduction of vaccination programs in lower-income countries, and may also help improve the relatively low vaccine coverage and series completion rates observed in some higher-income countries (Vaccine. 2018 Jan 2;36(1):98-106. doi: 10.1016/j.vaccine.2017.11.034. Epub 2017 Nov 23).
Anyone interested in future collaboration in this field of research is welcome to contact our key investigator Prof Ting Fan Leung, Chairman of our Department of Paediatrics. Prof Leung is an international expert in paediatric immunology, allergy and infectious diseases, and published over 280 articles in major journals.